APA (7th ed.) Citation

Lilienfeld-Toal, M. v., Agkatsev, S., Glasmacher, A., Reiß, P., Sen, S., Seltmann, A., & Wolf, S. (2025). Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022. ESMO open, 10(5), . https://doi.org/10.1016/j.esmoop.2025.105062

Chicago Style (17th ed.) Citation

Lilienfeld-Toal, Marie von, S. Agkatsev, A. Glasmacher, P. Reiß, S. Sen, A. Seltmann, and S. Wolf. "Letter Re: Ethnic Origin in Cancer Clinical Trials: Overrated or Understated? A Comprehensive Analysis of Cancer Clinical Trials Leading to FDA and EMA Approvals Between 2020 and 2022." ESMO Open 10, no. 5 (2025). https://doi.org/10.1016/j.esmoop.2025.105062.

MLA (9th ed.) Citation

Lilienfeld-Toal, Marie von, et al. "Letter Re: Ethnic Origin in Cancer Clinical Trials: Overrated or Understated? A Comprehensive Analysis of Cancer Clinical Trials Leading to FDA and EMA Approvals Between 2020 and 2022." ESMO Open, vol. 10, no. 5, 2025, https://doi.org/10.1016/j.esmoop.2025.105062.